September 15, 2025 — Leads & Copy — Interpace Biosciences, Inc. (OTCQX: IDXG) presented two new scientific posters at the 2025 American Thyroid Association® (ATA) Annual Meeting in Scottsdale, Arizona, September 10–14, 2025. The presentations highlighted the utility of Interpace’s ThyGeNEXT® + ThyraMIR®v2 testing in refining risk stratification of thyroid nodules.
One poster described how archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, potentially avoiding repeat FNAs. The other poster reported outcomes from 28,144 indeterminate nodules, demonstrating how ThyGeNEXT® + ThyraMIR®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative cases.
Tom Burnell, PhD, President & Chief Executive Officer of Interpace Biosciences, stated that these data continue to validate the real-world utility of their combination platform.
Dr. Temma Kaufman, MD, of Associated Pathologists PA, BayCare St. Joseph’s Hospital, noted the meaningful difference made by moving to a platform that accepts archival cytology slides, allowing them to obtain actionable molecular results in many initially insufficient cases.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
Source: Interpace Biosciences
